2022 / 06

Next Paper
DOI: 10.24075/brsmu.2022.065

ORIGINAL RESEARCH

The rs17713054 and rs1800629 polymorphisms of genes LZTFL1 and TNF are associated with COVID-19 severity

Traspov AA1, Minashkin MM1, Poyarkov SV1, Komarov AG2, Shtinova IA2, Speshilov GI2, Karbyshev IA2, Pozdniakova NV1, Godkov MA3
About authors

1 Sistema BioTech LLC, 109235 Moscow, Russia

2 State Budget Institution Of Health Of The City Of Moscow "Diagnostic Center (Center For Laboratory Research) Of The Department Of Health Of The City Of Moscow" Russian Federation, , Moscow

3 Sklifosovskiy Research Institute for Emergency Medical Aid, Moscow, Russia

Correspondence should be addressed: Natalia V. Pozdnyakova
1 Kurjanovskaja, 34, korp. 11, Moscow, Russia; ur.hcetoibametsis@avokayndzop.n

About paper

Funding: the study was supported by the major Sistema BioTech LLC shareholder, the Sistema Public Joint Stock Financial Corporation. The study was funded by the Moscow Department of Health as part of the double blind clinical trial.

Acknowledgements: the authors express their gratitude to Antipova YuO, Deputy Head of the Moscow Department of Health, for organizing the blind clinical trial of COVID-19 severity and the patients of the Diagnostic Center (Center of Laboratory Testing) of the Moscow Department of Health for the provided biomaterial samples.

Author contribution: Pozdnyakova NV, Poyarkov SV — study concept and design; Minashkin MM — molecular genetic research, laboratory tests; Poyarkov SV, Traspov AA — literature review, manuscript writing; Traspov AA — statistical processing of the results, manuscript editing; Komarov AG — project management, planning the experiment, data analysis; Shtinova IA, Speshilov GI, Karbyshev IA — providing clinical data and metadata; Godkov MA — control over clinical sample collection at the Sklifosovsky Research Institute for Emergency Medicine, providing anonymized data.

Compliance with ethical standards: the study did not need to be approved by the Ethics Committee because of dealing with anonymized patient data and the double blind study format.

Received: 2022-11-18 Accepted: 2022-12-14 Published online: 2022-12-28
|
Table 1. The main age and gender parameters selected for the study. The patients are divided into two groups based on the disease severity (the control group and the group of patients with severe disease), gender, and age
Table 2. SNPs used in the model for assessment of the risk of severe disease in two groups (control and experimental)
Note: CI values are provided only for odds ratios.
Table 3. Estimation of allele frequencies of 10 studied markers based on the dominant and recessive models, HOM1/HET/HOM2 genotype distribution, and significance of deviations from Hardy–Weinberg equilibrium (HWE p-value). Assessment was performed in the experimental (n = 340), control (n = 373), and combined (n =713) groups
Table 4. Estimation of the significance of differences between the experimental and control groups in 10 studied polymorphisms